ICU Medical Inc
NASDAQ:ICUI
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
84.39
183.83
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
ICU Medical Inc
Earnings Call Analysis
Q3-2024 Analysis
ICU Medical Inc
In the third quarter of 2024, ICU Medical reported revenue of $580 million, reflecting a 7% growth on a constant currency basis (6% on a reported basis). Their adjusted EBITDA stood at $95 million, with an earnings per share (EPS) of $1.59. Notably, gross margins exceeded expectations due to supply chain efficiencies and a favorable sales mix. The company generated healthy free cash flow, allowing them to reduce the accounts receivable factoring line, which highlights their improving liquidity position.
The consumables segment notably grew by 9%, driven by strong performances in infusion consumables, vascular access, and oncology. The ID Systems unit also excelled, growing by 10% in constant currency. ICU Medical emphasized their commitment to enhancing clinical outcomes and expanding their market share, underpinned by an ongoing innovation roadmap. For the rest of 2024, the company expects total results to exceed their previously stated mid-single-digit growth targets.
For the fourth quarter of 2024, ICU Medical adjusted their guidance, narrowing the adjusted EBITDA expectations from a range of $355 million to $365 million. Additionally, they increased their adjusted EPS forecast to between $5.40 and $5.70 per share, incorporating a tax benefit recognized in Q3. The guidance assumes a consistent demand environment for IV Solutions and no major disruptions in procedures, reflecting a cautiously optimistic outlook for the remaining year.
ICU Medical announced a significant joint venture with Otsuka Pharmaceutical focused on IV Solutions, motivated by recent challenges in the U.S. market. This partnership is expected to bring innovation and redundancy to the supply chain, potentially rectifying previous concentration issues. While ICU Medical will deconsolidate IV Solutions' revenues, they anticipate this move will maintain earnings stability. The early stages might not show immediate revenue growth, but the partnership is seen as a long-term strategy to boost market presence and improve product offerings.
The company finished the third quarter with a debt of $1.6 billion and a cash balance of $313 million. They anticipate further reducing reliance on their accounts receivable factoring program, which reflects improvements in cash flow management. In total, free cash flow for the year reached $109 million, exceeding their initial expectations. The company is focusing on utilizing cash reserves for debt paydowns and capital expenditures, which should promote stability and potential future growth.
ICU Medical's operational strategies include system integration and manufacturing consolidations expected to enhance profitability by 2025. They have already executed significant improvements in their U.S. operations, and are now optimizing logistics to further reduce costs. These actions are part of a broader strategy to elevate profit margins and align operational efficiency with market demands.
The IV Solutions market remains volatile due to various supply chain disruptions. ICU Medical's leadership emphasizes a long-term view on growth, focusing on diversification in supplier relationships and customer commitments. The joint venture with Otsuka is a proactive step toward reinforcing their market position amid these challenges. They enter this new venture with lessons learned from past disruptions, aiming not only to stabilize their supply chain but to innovate where it matters most.
You don't have any saved screeners yet
Good day, everyone, and welcome to today's ICU Medical, Inc.'s Third Quarter 2024 Earnings Conference Call. [Operator Instructions]
Please note, this call may be recorded, and I will be standing by if you should need any assistance.
It is now my pleasure to turn the conference over to Mr. John Mills. Please go ahead, sir.
Thank you. Good afternoon, everyone. Thank you for joining us to discuss ICU Medical's financial results for the third quarter of 2024. On the call today representing ICU Medical is Vivek Jain, Chief Executive Officer and Chairman; and Brian Bonnell, Chief Financial Officer. We wanted to let everyone know that we have a presentation accompanying today's prepared remarks. To view the presentation, please go to our investor page and click on the Events Calendar, and it will be under the third quarter 2024 events.
Before we start our prepared remarks, I want to touch upon any forward-looking statements made during the call, including beliefs and expectations about the company's future results. Please be aware, they are based on the best available information to management and assumptions that are reasonable. Such statements are not intended to be a representation of future results and are subject to risks and uncertainties. Future results may differ materially from management's current expectations. We refer all of you to the company's SEC filings for more detailed information on the risks and uncertainties that can have a direct bearing on operating results and financial position.
Please note that during today's call, we will also discuss non-GAAP financial measures, including results on an adjusted basis. We believe these financial measures can facilitate a more complete analysis and greater transparency in the ICU Medical's ongoing results of operations, particularly when comparing underlying results from period to period. We've also included a reconciliation of these non-GAAP measures in today's release and provided as much detail as possible on any addendums that are added back.
And with that, it is my pleasure to turn the call over to Vivek.
Thanks, John, and good afternoon, everyone. I'll quickly walk through our summary Q3 revenue and earnings performance as we believe the results are straightforward and then provide a few highlights on the various earnings and quality improvement efforts. Brian will take it from there for more specifics on the quarter and the balance of the year, then I'll come back with a discussion on the strategic joint venture we just announced today with Otsuka and the overall situation around IV Solutions and the implications for our customers and ICU Medical with this transaction.
Revenue for Q3 was $580 million for total company growth of 7% on a constant currency basis or 6% on a reported basis. Adjusted EBITDA was $95 million and EPS was $1.59. Gross margins were a little higher than expected due to capture of supply chain efficiencies, FX and sales mix. We again had a good quarter of free cash flow generation, which enabled us to reduce some of the AR factoring line as previously discussed, and our cash balance increased to approximately $313 million.
The broader demand and utilization environment in Q3 was healthy across all geographies and has felt that way this year to date. And since we're almost halfway through Q4, we've not really seen any major changes in the environment. The capital environment was status quo and the investments that customers need to make are getting made. Then finally, we had a quarter with the net impact of foreign exchange in our favor.
Getting into our business units more specifically. Consumables grew 9% on both a constant currency and reported basis. The largest lines in this segment in order, Infusion Consumables, Vascular Access and Oncology, all grew high single digits or better. We continue to advance the points made on previous calls around focusing on clinical outcomes, new market creation and improving in geographies where we had a low share and now have direct operations. And we're focused on progressing the innovation road map as we've mentioned previously.
For the balance of 2024, nothing else is new here, and we would expect the full year results likely to finish above our original mid-single-digit targets with the legacy ICU consumables lines being at the current levels. Our ID Systems business unit grew 10% constant currency and 7% on a reported basis. We had more balance across the product lines here as compared to Q2, sequentially off the very strong Q2 for ambulatory hardware devices, those levels decreased and the install calendar for LVPs was stronger than Q2, and therefore, we saw sequential growth in the LVP line.
Some key highlights here include continued new contract signings for our Plum Duo infusion system, and we're pleased with what we're seeing so far. We continue to advance our 510(k) submissions for our Plum Solo and LifeShield safety software. We have received FDA feedback on those submissions, and we're working to clear up the open questions. After these products are cleared, the combination of the dual channel, Plum Duo and the single channel Plum Solo will provide customers flexibility across all clinical care areas, and our energy will shift towards the refreshed syringe platform of Med Fusion with the goal of filing that 510(k) submission over the next several quarters and having it connect to our LifeShield safety software as well.
Our ambition is to have the most modern fleet of infusion devices that can anchor the portfolio for many years to come. Simplistically, we want customers to have the right tools for the right job, all connected with a common user interface and a software solution that minimizes training, improves onboarding enables interoperability and drive standardization. For the balance of 2024, nothing else is new here, we would expect results in line with our original targets.
Just wrapping up the business segments. Our Vital Care segment was flat year-over-year on a constant currency and reported basis. Obviously, since the day of first day of Q4, there's been a lot happening in the IV Solutions marketplace, and we'll discuss that when we explained the choice to enter this new joint venture.
From an operations and quality standpoint, the cutover of our U.S. and Canada order-to-cash systems was executed in Q3, and many thanks to the numerous folks who went above and beyond to make this as smooth as possible. Now that this work is under our belts, we're focused on optimizing our North American physical logistics and then we'll begin these activities internationally. We continue to work on the previously announced factory consolidations with essentially most projects completed by the end -- intended to be completed by the end of 2025. The vast majority of our real estate contracts have now been exited or repriced and savings in this area will come into the P&L over 2025 and beyond.
While these may seem like mundane topics, all 3 items I just mentioned are economically meaningful and contribute to improving our profitability level.
From a quality perspective, we believe we've launched the majority of field corrective actions as we needed to stabilize the acquired LSM products. There will be a few more here, but we're optimistic that they will be smaller, both in terms of absolute number and scope. In Q3, we also had a very detailed FDA follow-up inspection relating to the acquired warning letter at our Minneapolis site. That inspection was completed with no observations and is an important part of our quality improvement journey, and we're awaiting our end of inspection report.
That's really the quick update on Q3. And with that, I'll turn it over to Brian, and then I'll come back to talk a bit more about IV Solutions and our newly announced joint venture.
Thanks, Vivek, and good afternoon, everyone. Since Vivek covered the Q3 revenue for each of the businesses, I'll focus my remarks on recapping the Q3 performance for the remainder of the P&L as well as the Q3 balance sheet and cash flow and along the way, provide commentary on any implications to our expectations for the full year.
As you can see from the GAAP to non-GAAP reconciliation in the press release, adjusted gross margin for the second quarter was 37%, which was slightly better than our expectations. Similar to the first half of the year, we experienced favorable product mix with a higher proportion of disposables revenue relative to hardware during the quarter compared to our plan, along with the benefits from supply chain synergies as we make progress towards capturing the balance of $50 million of synergies over the next few years.
In the third quarter, we also experienced a more favorable foreign currency environment compared to the first half of the year, whereby the U.S. dollar weakened relative to the currencies in our key selling geographies and at the same time, strengthened versus the Mexican peso, which is our primary manufacturing foreign currency.
For Q4, we expect gross margins to be in the 36% to 37% range, reflecting the additional benefits from continued capture of synergies, offset by the impacts of two items, the first of which is the expected higher revenue mix of IV Solutions which has a lower gross margin profile; and the second being the recent reversal of the favorable foreign currency environment we experienced in Q3 as the U.S. dollar has now strengthened relative to our selling foreign currencies.
Adjusted SG&A expense was $120 million in Q3 and adjusted R&D was $20 million. Total adjusted operating expenses were $140 million and represented 24.2% of revenue. Both the total dollar amount of spend and spend as a percentage of revenue were exactly the same as Q2. On a year-over-year basis, total operating expenses were up 11%, reflecting a combination of increased selling expenses from higher revenues and higher incentive compensation.
Restructuring, integration and strategic transaction expenses were $17 million in the third quarter and related primarily to IT system integration and manufacturing network consolidation. Adjusted diluted earnings per share for the quarter was $1.59 compared to $1.57 last year. The current quarter results reflect net interest expense of $25 million. The third quarter adjusted effective tax rate was 20% and includes a discrete benefit related to U.S. federal return to provision adjustments, which contributed approximately $0.10 per share.
For comparison purposes, the prior year tax rate reflected discrete benefits, which contributed approximately $0.25 per share. Diluted shares outstanding for the quarter were 24.6 million. And finally, adjusted EBITDA for Q3 increased by 6% to $95 million compared to $90 million last year.
Now moving on to cash flow and the balance sheet. For the quarter, free cash flow was $16 million, which includes the impact of a $26 million outflow related to lower utilization of our accounts receivable purchase program. It was another solid free cash flow quarter when taking into consideration the impact from lower usage of the receivable program. We mentioned during the Q2 call that we expected to reduce our usage of the program during the second half of this year as our liquidity position continues to improve.
As of the end of the quarter, we had $27 million outstanding under the program, and we expect this balance to further reduce by year-end. During the quarter, we invested $8 million of cash spend for quality system and product-related remediation activities, $17 million on restructuring and integration and $20 million on CapEx for general maintenance and capacity expansion at our facilities as well as placement of revenue-generating infusion pumps with customers outside the U.S.
And just to wrap up on the balance sheet, we finished the quarter with $1.6 billion of debt and $313 million of cash. As we think about cash flows over the near term, there are a couple of items worth mentioning. First, as discussed on the last call, we believe the current cash balance is adequate to support the day-to-day liquidity needs of the business, and we would anticipate any further increases to the cash balance to be used for either early paydown of term loan principal or reducing usage of the accounts receivable factoring program. And second, year-to-date free cash flow is $109 million, which is already ahead of our original full year guidance.
For the fourth quarter, we don't expect the same pace of cash generation as the fourth quarter typically has higher cash outflows for capital expenditures and tax payments. Plus, there is the potential reduction in the utilization of our receivable factoring program given our improved liquidity position.
During the second quarter earnings call, we provided updated full year adjusted EBITDA and EPS guidance. Based on our Q3 results as well as the latest outlook for Q4, we are narrowing and raising the midpoint of our previously provided adjusted EBITDA guidance range of $345 million to $365 million to a range of $355 million to $365 million.
For adjusted EPS, we are raising our previously provided guidance range of $4.95 to $5.35 per share to $5.40 to $5.70 per share, reflecting the improved outlook for adjusted EBITDA plus the previously mentioned $0.10 tax benefit recognized in the third quarter. The guidance assumes higher demand for IV Solutions, a commercial environment consistent with the third quarter, including no material impact from the deferral or cancellation of procedures and today's foreign currency rates.
And for modeling purposes, you can assume Q4 net interest expense of $24.5 million, a Q4 adjusted tax rate of 24% and Q4 diluted shares outstanding of 24.6 million. To wrap up, we're happy with our performance for the first 3 quarters of the year, including improvement in our gross margin rate, better-than-planned free cash flow generation and an improving balance sheet. We remain focused on the foundational work that will drive earnings improvement in 2025 and beyond.
And now I'll hand the call back over to Vivek, who will provide more specifics on today's announced IV Solutions joint venture.
Okay. Thanks, Brian. I'll spend the balance of the time on what's happening with our IV Solutions business and our excitement about the joint venture we're announcing, why Otsuka is the best partner in the world for us, how this will be a great outcome for our customers and the broader North American market, our strategic thinking on why this structure and some economic implications for ICU Medical.
Obviously, the U.S. IV Solutions market has been impacted by the events in North Carolina, and we empathize with the people and customers impacted by the crisis. We had and still have unabsorbed capacity in our Austin location and have been ramping up to first ensure our long-term committed customers are well served and to be able to help new systems that are willing to make longer-term commitments as we learned a few lessons in our experience through Hurricane Maria. Frankly, we've seen the best of customers and human nature in these moments. And we've also seen some of the characteristics that led to the market concentration that the country has faced.
On these earnings calls for years, we've talked about the intrinsic value of IV Solutions being out of line with its economic price. Maybe a simple analogy, it's the $0.10 screw that keeps the wheels on the bus. We've spent years pitching geographic diversification. We went as far as asking the GPOs if they wanted to buy into our business over the years. And we've read the same articles in these times of crisis, arguing that the government should mandate diversification when it practically has very few tools to do so and the market has chosen not to.
Yet there are -- yes, there are certain customers who get it and are willing to do the work to diversify. But our conclusion, which predates the current crisis is that there has to be better choice in the market as defined by product breadth, supply reliability, innovation, geographic diversity, the ability to invest and then maybe the market itself will work and balance the risk better across suppliers. That's why we're so excited to announce the creation of a manufacturing and innovation joint venture with Otsuka Pharmaceutical Factory around IV Solutions. They are the single best partner on the planet for us, and I'll go through the reasons why that's the case on the attached slides that follow the revenue schedule in our investor presentation.
And just to preempt the question, this is not some hastily arranged shotgun relationship. I first met with this company over a decade ago on other product categories. We were in some conversations in 2019 pre-COVID and we've spent the better part of this year exploring this opportunity with hundreds of hours of technical reviews, site visits across continents and building a relationship and shared vision about something that could last for over the next decade.
First, just a few facts about Otsuka on Slide 5 and 6. They are a Japanese global health care company that's been in business for over 100 years and are an active participant in branded pharma in the U.S. market. The stats on the right-hand side of the slide are self-evident, but they have a big pharma-like balance sheet and capitalization, which is different than all the current public company suppliers of IV solutions, including ourselves. Their IV solutions portfolio is part of their original business, and they're the largest supplier in Asia, and we believe they have the best innovation of any global supplier. That innovation is everything from packaging, being the world's only producer of a 4-chamber TPN bag to very cool admixture and reconstitution formats to all materials being PVC-free across the entire portfolio, to core pharma competency around formulations and stability to fit with the other skills.
Slide 6 shows some of this track record of innovation.
Slide 7 outlines the core reasons we were attracted to them, if not obvious, already. Our main reasons were scale and redundancy, innovation, the cultural mindset, financial strength and the experience in U.S. partnerships. Key highlights of the transaction are at the bottom of the slide, which is an upfront payment to ICU Medical, a milestone after a milestone payment potentially after 2 years and a put call option for either party starting in 2030, shared governance, et cetera.
From an ICU perspective versus our other lines of business, it's been hard for us to drive meaningful innovation in the IV Solutions category. And our business generally set alone as a domestic-only enterprise in Austin, Texas.
Slide 8 shows Otsuka's global manufacturing footprint, and Austin will join 16 owned Otsuka sites with a long-term goal of FDA approval at a number of these locations to create more redundancy.
Just one comment on Slide 9. In a long-term partnership, culture and alignment matters, they operate with a long-term mindset backed by financial strength and experience. They operate in geographies faced with natural disaster risk daily and the commitment to new production technology, combined with risk mitigation, is ingrained in their culture, and I've seen firsthand how they've hardened their sites in Japan.
From a customer perspective, we want to bring more innovation along with clear supply redundancy to allow the market to fix the concentration problem.
We love this structure outlined on Slide 10, the key items slide, because it creates something that will be seamless to customers. On the front end, it will feel exactly the same to customers with us providing everything as we currently do, sales, logistics, billing, et cetera, but with additional resources on the manufacturing side. We've also stated on these calls for years that IV Solutions should be priced relative to its own individual intrinsic value. If the market continues to combine this category with other infusion items, we can stay in this structure or if the market separates these items in the next GPO cycle 1 after that, we have a put call structure that allows us to make those decisions after a minimum of 5 years.
To conclude this discussion, we are really honored that Otsuka chose to work with us and look forward to many years of a fruitful partnership. Now there will be implications for ICU Medical. It was a tough call to make, but it was an important for Otsuka to be able to consolidate the revenues of the joint venture. So as a result, ICU will deconsolidate IV Solutions' financial results and recognize only our proportional share in the net earnings of the JV. While it's painful to give up so much revenue, we do believe with the upfront payment, the transaction will be EPS breakeven to ICU. Simply stated, the interest expense savings from debt paydown from the upfront $200 million payment equals the current EBIT contribution of the business.
We have to work through the financial reconciliations between now and closing. But net-net, our gross margin will change between 300 to 400 basis points initially after close and could reach 500 basis points as the JV stands up its own services, but that will take some time. We would have to subtract around $25 million in annual EBITDA from our roll-up next year, and we believe the JV will be able to sustain its own CapEx and we can make other choices with that capital.
In the bigger picture of ICU, on the last few calls, we've talked about revenue stabilization and the ability to grow our differentiated product lines as demonstrated in Q3. While it's nice to have that revenue growth now, it's not lost on us that we're still under-earning as a company relative to the industry as evidenced by the fact we had higher earnings with less revenues historically.
This JV does not solve that issue on an absolute basis even if some of the margin ratios change. We continue to be extremely focused on all the actions to improve profit in the medium term, which are about revenue growth, mix and pricing, operational efficiency from my introductory comments and eventually waiting for the macro items and currency and interest rates to improve. Where this JV does impact us is how long we can bear interest expense to make sure we're maximizing the value of any of our other assets.
Net debt at the end of Q3 was about $1.3 billion, as Brian referenced, between our mandatory principal payments of around $75 million-ish in 2025 plus $200 million in paydown of the term loans from this situation, it would put us approximately around $1 billion of net debt by the end of 2025. If earnings can continue to improve alongside an improving interest rate environment and lower leverage ratio spread, perhaps we can think about other ways to return capital to shareholders over time.
Again, all of this has to happen, but it's certainly not out of the range of potential outcomes. To be direct on our goals for the next year or 2, we want our consumables and systems business to be reliable growers with an industry acceptable profit margin with the tightest and most optimized manufacturing network and each with a multiyear innovation portfolio, and we ultimately want to transfer value from debt to equity, which Brian noted, we are finally better prepared to move on.
There is no confusion within the company in the pursuit of these goals, and we don't have any frivolous activities here. We produce essential items that require significant clinical training, hold manufacturing barriers and in general, are items that customers do not want to switch unless they must. The market needs ICU Medical to be an innovative, reliable supplier and our company is stronger from all the events over the last few years and the good news of today.
Thank you to all our team members and customers as we improve each day. With that, I'll open it up to questions.
[Operator Instructions]
We'll go first to Brett Fishbin with KeyBanc.
Vivek, you definitely gave a lot of detail around why this was the best partner in terms of entering this type of JV arrangement. Was just curious if you could give a little bit more around the strategic thought process of going in this direction with the JV, whether you guys consider to sell. And then why you think sticking around in the solutions business for the foreseeable future is the best decision for the company.
Sure, Brett. I don't think we ever had any considerations about a sale. It's a core product for our customers that's deeply linked with the other things that we do. I think where we struggled was what I tried to outline in the script is trying to be the best innovator we can be on pumps and software, trying to be the best innovator around consumables and category creation. It was hard for us to do all of it. And our portfolio was a little narrower here than some of the other players. We were looking for a way to stay in the market still absolutely deliver these items to our customer but make sure we could bring the innovation that could be more relevant to them and diversify the market a little bit.
And for us, like the choices in the other ategories who came down to who had market leadership around the world and the other geographies and who have the most innovation.
All right. I appreciate that color. And then just one question on the ERP. You touched on it briefly. I believe that you've now completed the U.S. and North America portion of it, and it sounds like it was relatively successful. Just curious if there was any disruption intra-quarter from that at all. And what kind of incremental benefits you might be seeing as we progress into the fourth quarter?
I mean there was certainly disruption to the team members' lives during the quarter. We have to deal with it, ourselves included. I -- it's a lot of work, a lot of people sacrificed. I mean during, I would say, the month of August, yes, there was a little bit of bumpiness. We had the month of September to clean up some of those items, but it only gets cleaned up because people gave a lot.
Brett, to your point, I would say that although there was some volatility during the quarter, the quarter itself really wasn't impacted at all when you look at it kind of in total. So from my standpoint, as CFO, that's the definition of success.
We'll go next to Eric Fleming with Raymond James.
On for Jayson tonight. A couple of quick questions. On the LVP on Duo. Have you been able to hold the pricing levels that you were talking about earlier this year?
I don't know that we've publicly articulated the pricing levels, but I would say we recognize that you don't have many chances to have new technology reset in the market. We believe in the technology. We want customers who believe in that. We're focused on holding that level. We have not made any changes to where we thought we would start marketing that product.
And how is the market share looking with everyone now back on the market?
I mean again, I think everybody -- it's obviously -- it's a very hot topic given all the competitors' comments on it. I think we feel good about the cards we're holding. We feel good about it from a competitive standpoint with Duo in the market and the amount of conversations. And again, we were very transparent on the power of incumbency, et cetera, on the previous calls. It's all relative to the size of our business, which frankly isn't that big in the U.S. And we feel very good if Solo comes and the ability to access our own installed base, where our equipment is finally aging out and needing a little bit of refresh. So I think we feel good on both of those fronts. And then the CAD product is almost a separate conversation, but continues to be the best asset that came with the acquisition.
Sorry, and one other follow up -- not follow up, another question. On the Mexican peso, with the recent election results, what's the outlook in terms of any potential tariffs and the impact on the benefit you're getting in the [indiscernible] right now?
I mean I think obviously, it's unclear. Last time around, it was not particularly meaningful. I would say, we are a bit player of the amount of stuff coming from Mexico, not only in the health care industry, but automotive consumer whatever will all be treated same way. Right now, we're not sitting around and spending a lot of time planning on that scenario.
And then just sorry, one last one. You mentioned the FDA has inspected that Smiths facility with the warning letter and you're just awaiting the final report. Is that correct?
We said at the site, at the site that where the warning letter was issued, we did have a very thorough follow-up inspection. We had no observations. That's one of the components to getting a full clean bill of health. It's the hardest and most strenuous one. And so that box got checked. At the end of that, you're issued an end of inspection report, you could receive that any number of months after the inspection, and we don't have that in hand yet.
[Operator Instructions] We'll go next to Larry Solow with CJS Securities.
Okay. I guess just going back to the strategy of the deal. I guess you kind of get the best of both worlds in that, you can still control the solutions piece and enable it to sell it with the systems and consumables, while you also have another partner helping, I guess, take 50% of that investment and also you're adding I assume some complementary products that they're bringing as well as the manufacturing redundancy. So to me, it seems like almost a win-win if I'm looking at that correctly.
We thought about it a lot. I appreciate the comments are. We thought about it a lot. It's obviously joking aside, it's a very fluid time in the market. We tried to come up with a structure that protected us in the near term, sort of in the medium term and maybe hedge a little bit of the risk we have today, but certainly kept us in the business for the long term, if we can do what we think we can do together. So we are -- we really think we kind of win-win on the structure. And it's -- we have searched for this for a long time. It's not easy to do. It took a long time.
And the valuation, right. And the valuation looks like at 16x EBITDA, I guess there must be Otsuka must have and you as well, think that this number is certainly a depressed number for the last couple of years. So I'm sure there's some low-hanging fruit just on pricing and things, but then the ability to add their products into our distribution network, I guess, brings that up a lot more potentially. But I guess the question I have is there's a decent amount of assets right on your balance sheet tied to solutions that, I guess, will come off in the deconsolidation. Is there any way to frame that?
Yes, Larry, it's Brian. Your question around multiples, which we don't really pay attention to, I think it's probably closer to 13x or something like that rather than the 16 you mentioned, but we think it's representative of the value of the business, of course, and the value that can be created as -- with our partners. Yes. And then, of course, I guess just from an accounting standpoint, we will deconsolidate the financial results as well as kind of the assets and liabilities on the balance sheet.
I think the decision-making structure was 1 part of Larry, the other decision-making was fundamentally about is this better for customers? Is it better for the marketplace to check the boxes that help undo the concentration from by bringing innovation and more choice. And we looked in the merit at every 1 of those. We felt like this will be better for the marketplace, better for customer. We couldn't get there on our own.
Got you. Great. And if I could just squeeze 1 more question just on the gross margin. Independent of the lift you expect from the deconsolidation, but just on the core or the entire business ex the solutions piece. You've captured it sounds like some supply chain efficiencies or expedited those in the last couple of quarters. Are those kind of just a little bit faster than you assumed you get them but nothing really to -- perhaps the outlook for next year doesn't really change that much? You've just gotten a little bit better this year faster? I guess question one. And then do you still expect consolidation to drive like a 200 basis point improvement in gross margin, plus or minus, [ 26 ] when you get the full year benefit?
Yes, Larry. So on the 2 questions, one, as it relates to the favorability we saw in Q3, yes, we're getting those synergies a little bit sooner than expected. We've talked about $50 million is kind of what we expect as a part of Phase 2 in total. Most of that's going to show up in the gross margin line. And we -- but we still think that the time line for capturing everything is by the end of next year. So we're still -- we just happen to be a little bit ahead of schedule. So I don't think it really changes the opportunity.
I just want to rephrase. I'm sorry, Brian, I felt like the projects that we only done by the end of next year, right, by taking longer the projects will be done. I think, Larry, I would focus on the gross margin percentage. We've been very clear, Brian, in every script. We had a target of [ 40 ] that we wanted to get to. And that [ 50 ] was part of [indiscernible]. So it's all relative to where we are against that target.
Yes. Vivek referenced as it relates to the joint venture and margin impact there, the remaining 1 to 2 percentage point change would probably be coming later on than 2026 when the joint venture would potentially be stand a little more on its own as it relates to certain commercial type of activities.
Right. Got you. And then to get to [ 40 ], but just do the math just with the deconsolidation alone from where we are today are pretty close, right?
Yes.
We'll move next to Kristen Stewart with CL King.
I was wondering if you could just share a little bit more details on what you're seeing today with IV Solutions and your ability to ramp up manufacturing, how much you're able to ramp up to really take advantage of the dislocation from your competitor?
I mean we feel, Kristen, let's go back, thanks for the question. We feel like we're not interested in really playing a short-term game. We got burned on that in Maria and our prize at the end of that was going to have to restructure our business back then, and we don't want to do that again. And so for us, the business we're interested in is if truly people want to diversify and take a long-term view on their either Dual or Solo, whatever may be supply, I don't think we're running around trying to be opportunistic. And part of this decision on this partnership was saying, we thought by bringing these set of skills and redundancy and innovation together, we could wind up with higher market share than we have today over time. It wasn't about exploiting what's going on right now. And it's a very awkward time for customers because we certainly believe that just like what happened Maria, the situation will get rectified. People will come back and there will be adequate supply in the market. I think no one has -- we certainly don't want to speak for anybody, but no one has the illusion that share -- that capacity is not going to come back on line, absolutely. So for us, it is much more about the long term.
We'll move next to Mike Matson with Needham & Company.
Yes. I've joined the call late, I apologize if you've gone through this. But just on this deal, it's going to be a JV. So all the -- is there any revenue benefit to ICU once the deal is completely set up? Or is all that revenue going to be flowing through the JV?
So Mike, just I guess kind of how do the activities of the joint venture show up in our P&L. We will deconsolidate the results. So on the P&L, all we will show is the -- our portion of -- in the net earnings of the joint venture. So we will benefit economically from any incremental revenues if they generate incremental profits, but it doesn't -- it won't show up on our revenue line.
Okay. Got it. And then just your sales team would be selling the IV solutions or I mean, would those people move over to be part of the JV? Or I guess...
Yes. Mike, it's commercially. Everything to the customer remains exactly the same. You ordered via ICU, ship via ICU. We run the warehouse, et cetera, we bill. Now those may be services that are provided on behalf of the JV, but the whole experience is seamless to the customer and the integrated value that's delivered, meaning the co-mingling of the value prop of some of these products across other infusion items continues because it's all held together commercially. The revenue benefit is really one of -- there's two different parts of that question. One part of the that is if we believe on our own, we had a better chance of the first 2 pillars of our company that we described in the call, the infusion consumable, the infusion pumps growing at a superior growth rate to solutions over time, it could be revenue growth accretive. That may not be the case in the short term, given what's going on.
But the idea is the experience for the customer will feel exactly the same as it does today.
Yes. Okay. Yes, that makes a lot of sense then. So you're kind of potentially removing a slower growth business and but maintaining the benefits of bringing that along with everything else to the table for the customers.
I mean just to be super blunt about it, over the -- if we learned, yes, there's some shortage today, but if we learned what happened last time, and we learned what happened to the people who supply things during COVID, the market has happen -- vaccines, ventilators, testing, whatever you want, the market has a chance of reverting to the mean, rather, even if there's some uplift in recognition of the value of this market, the only way to make it a faster growth business for us was with more innovation, and we need a partner to help us do that.
Okay. Got it. And then just want to ask one on the pump market and competitive dynamics there. So I guess I don't cover Becton, but just looking through their comments, it sounds like they kind of -- they're saying, at least that they're delivering on what they thought they could do in terms of reentering that market. So what are you seeing? And how -- to what degree have you been able to pick off share from them or other players?
It's an active market because a lot of people are forced to make a decision right now. I think, again, we've grown up in this business and our comments in the last couple of calls here's a huge advantage to incumbency to all players. But again, relative to our LVP size, which wasn't that big, there's enough choices out there to have us certainly get a meaningful return on our R&D investments into the Plum Duo and Plum Solo programs, and there's more conversations going on than there ever have been. We certainly think a huge majority of people generally stay with the incumbent, but the amount of market that needs to change is plenty for us to grow [indiscernible].
We will go next to Michael Toomey with Jefferies.
Most have been answered already, but just on the Otsuka JV. What would the free cash flow accretion look like for the deal? How much funding would that need on a CapEx perspective? I know you said it's neutral on adjusted EPS, but just on the CapEx and free cash flow.
I would say, Mike, in terms of free cash flow, marginally positive, neutral to marginally positive for us.
I mean we haven't had -- Mike, welcome to the call, by the way. It's not like we had tons of excess cash lying around the last year or 2. There are some spots we want to invest in wouldn't -- some of the production assets in the other areas, I wouldn't assume like it changes the overall cash flow picture that much. It may just get reinvested in some other areas that are -- we can make more of a difference.
We'll return now to Brett Fishbin with KeyBanc.
Just wanted to clarify one point. So yes, I totally appreciate the comments around like short term versus long term and in full agreement. Just wanted to see, you did mention that there was some incremental capacity if there was some additional revenue or EBITDA that you're expecting to realize from that increased demand in the fourth quarter and what's included in guidance.
We just haven't thought about it that much. Brett, we're going as fast as we can go. And we're doing that on the belief that there will be enough volume that's sustainable there. We're really not sitting around looking at it on a short-term basis.
All right. Fair, fair enough. And last question for me. Just can you explain any more you can about the put call option that's embedded in the JV agreement and what the mechanics look like at a high level?
It will all be public in our filings over the next couple of days or weeks, whenever they go in. Essentially, it's an option that goes out a decade can't exercise an option until the fifth year. And that option is based on a multiple of revenues. So if the market grows and expand in value, we participate in that and we receive a multiple of revenues times our ownership percentage. And so it's an incentive to keep growing the business, to make it as large and relevant to customers as possible.
And vice versa, if companies only wound up supplying, call it wet items, if customers really want to buy fluids or solutions individually, a call option exists if there's no need to have some of these items together. But no one really knows today how the market is going to develop. And I think it's the best of all worlds as we can figure it out as it comes and to the customer, it just needs to be seamless.
And with no other questions holding, I'll now turn the conference back to our presenters for any additional or closing comments.
Thanks, everyone, for your interest in ICU Medical. Sorry, the call was so late. We were obviously busy trying to get stuff done. I think this is setting the latest in the quarter, and we've done it, and we will make sure it happens faster in the future. Have a good fall and talk to you soon. Thanks very much.
This does conclude today's call. We thank you for your participation. You may disconnect at any time.